Compare Lowe`s Companies Inc (LOW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Lowe`s Companies Inc trades at $191.26 (market cap $105.89B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Lowe`s Companies Inc is far larger — about 21.7× Travere Therapeutics Inc. Common Stock's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LOW | TVTX | |
|---|---|---|
Market Cap | $105.89B | $4.88B |
Volume | 3,104,115 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $67.52 |
52-Week Low | $179.50 | $26.79 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $144.74B | $5.01B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.36, up 1.5% with recent earnings beats but facing industry headwinds. The stock shows bearish technical signals despite positive analyst sentiment with a $244.09 consensus target. Revenue declined to $83.67B in 2025, though net margins remain healthy at 7.35%. Recent drone delivery initiatives with DoorDash and Alphabet aim to enhance competitiveness amid a challenging home improvement market.
LOW presents a value opportunity with reasonable P/E (15.95) and strong cash flow, but risks include declining revenue trends, high debt levels, and housing market sensitivity. Wall Street maintains bullish ratings (61% buy) despite near-term pressure, suggesting potential upside if execution improves.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
